girentuximab

Home » Classic Medicine » Pharmacology » girentuximab
girentuximab2016-11-15T06:01:43+00:00

girentuximab 

ONCOLOGY, THERAPEUTICS

A chimeric IgG1 monoclonal antibody that targets carbonic anhydrase IX, which is overexpressed in clear cell renal cell carcinoma. The Phase 3 ARISER study using girentuximab as monotherapy in patients with clear renal cell cancer is on-going but not recruiting patients. ARISER’s next milestone was a total of 343 relapses; interim analysis is planned. 

*Phase 1/2 studies of girentuximab plus low-dose IFN-alpha in patients with progressive metastatic renal cell carcinoma indicated that the combination therapy was safe, well-tolerated and demonstrated clinical benefit in the patient population. 

Other names WX-G250; WILEX 

Reference http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038014/

Leave A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.